PL432676A1 - Preparation of bosentan in the form of orodispersible tablets - Google Patents

Preparation of bosentan in the form of orodispersible tablets

Info

Publication number
PL432676A1
PL432676A1 PL432676A PL43267620A PL432676A1 PL 432676 A1 PL432676 A1 PL 432676A1 PL 432676 A PL432676 A PL 432676A PL 43267620 A PL43267620 A PL 43267620A PL 432676 A1 PL432676 A1 PL 432676A1
Authority
PL
Poland
Prior art keywords
preparation
bosentan
orodispersible tablets
orodispersible
lyophilization
Prior art date
Application number
PL432676A
Other languages
Polish (pl)
Other versions
PL241575B1 (en
Inventor
Grzegorz HUSZCZA
Urszula Szewc
Małgorzata SKAŹNIK
Aleksandra Dworzyńska
Original Assignee
Sieć Badawcza Łukasiewicz - Instytut Farmaceutyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sieć Badawcza Łukasiewicz - Instytut Farmaceutyczny filed Critical Sieć Badawcza Łukasiewicz - Instytut Farmaceutyczny
Priority to PL432676A priority Critical patent/PL241575B1/en
Publication of PL432676A1 publication Critical patent/PL432676A1/en
Publication of PL241575B1 publication Critical patent/PL241575B1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest preparat farmaceutyczny w postaci tabletek ulegających rozpadowi w jamie ustnej zawierających substancję czynną bozentan lub jego farmaceutycznie dopuszczalną sól lub solwat, zapewniający czas rozpadu w jamie ustnej poniżej 10 sekund. Przedmiotem zgłoszenia jest też sposób otrzymywania ww. preparatu. Preparat otrzymuje się metodą liofilizacji.The present invention relates to a pharmaceutical formulation in the form of orodispersible tablets containing the active ingredient bosentan or a pharmaceutically acceptable salt or solvate thereof, which provides a disintegration time in the oral cavity of less than 10 seconds. The subject of the notification is also the method of receiving the above-mentioned preparation. The preparation is obtained by lyophilization.

PL432676A 2020-01-23 2020-01-23 Preparation of bosentan in the form of orodispersible tablets PL241575B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL432676A PL241575B1 (en) 2020-01-23 2020-01-23 Preparation of bosentan in the form of orodispersible tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432676A PL241575B1 (en) 2020-01-23 2020-01-23 Preparation of bosentan in the form of orodispersible tablets

Publications (2)

Publication Number Publication Date
PL432676A1 true PL432676A1 (en) 2021-07-26
PL241575B1 PL241575B1 (en) 2022-10-31

Family

ID=77077886

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432676A PL241575B1 (en) 2020-01-23 2020-01-23 Preparation of bosentan in the form of orodispersible tablets

Country Status (1)

Country Link
PL (1) PL241575B1 (en)

Also Published As

Publication number Publication date
PL241575B1 (en) 2022-10-31

Similar Documents

Publication Publication Date Title
MX2023000835A (en) Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof.
PH12020550341A1 (en) Niraparib formulations
MX2019011491A (en) Niraparib formulations.
IL187383A (en) Dispersible bosertan tablet
CO5390076A1 (en) PHARMACEUTICAL COMPOSITIONS
HUP0105173A2 (en) Dosage regimen and pharmaceutical composition for emergency contraception
JP2018035202A (en) Pharmaceutical composition containing irbesartan and amlodipine or salt thereof
PH12019502566A1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MX2023009833A (en) Centanafadine pharmaceutical formulations, and methods of making and using same.
FI3769765T3 (en) Pharmaceutical composition including sodium alkyl sulfate
NO20070952L (en) Formulations of suberoylanilide hydroxamic acid and processes for their preparation
PL432676A1 (en) Preparation of bosentan in the form of orodispersible tablets
MY191983A (en) Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same
EA202193065A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AXITINIB
WO2019016673A3 (en) A stable oral pharmaceutical composition of imatinib
JP6863401B2 (en) Solid preparation
PL432480A1 (en) Eplerenone preparation in the form of orodispersible tablets
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
MX2022001746A (en) New fosfomycin tablet formulations.
JPWO2018021265A1 (en) Composition for adding orally disintegrating tablets
JP6893687B2 (en) Orally disintegrating tablet
PL434081A1 (en) Preparation in the form of coated tablets containing a high dose of temozolomide and method of its production
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.
JP6795330B2 (en) Composition for oral mucosa containing triamcinolone acetonide